期刊文献+

83例原发性肝癌患者自身抗体检测结果分析 被引量:3

Analysis of autoantibodies in 83 patients with primary hepatic carcinnoma
下载PDF
导出
摘要 目的:探讨原发性肝癌患者自身抗体产生的规律及临床意义。方法:以临床诊断为原发性肝癌患者83例作为研究对象,采用间接免疫荧光法及免疫印迹法检测患者血清中自身抗体。结果:83例肝癌患者自身抗体检出率为37.3%(31/83),其中HBV感染患者检出率35.9%(23/64),HCV感染者检出率50.0%(8/16),二者差异无统计学意义(P>0.05)。能检测到一种、两种及三种自身抗体的患者分别为24.1%、12.1%和1.2%。抗核抗体(ANA)、抗细胞骨架抗体(CS)、抗平滑肌抗体(SMA)和抗线粒体抗体(AMA)的检出率分别为24.1%、13.3%、9.6%和4.8%。抗核抗体谱分析有Ro-52、CENP-B(着丝点B抗原)等自身抗体阳性。AFP(甲胎蛋白)异常及AFP正常的患者自身抗体检出率分别为36.8%和22.2%,差异无统计学意义(P>0.05)。HBV-DNA阳性与HBV-DNA阴性患者自身抗体检出率分别为40.5%和27.3%,差异无统计学意义。女性患者自身抗体检出率明显高于男性,差异有统计学意义。结论:37.3%的原发性肝癌患者能检测到非器官特异性的自身抗体:ANA、CS、SMA和AMA,大多患者以检出其中一种抗体为主,部分患者能检出二至三种自身抗体。ANA、CS、SMA和AMA四种自身抗体中检出率最高的是ANA,其次是CS和SMA,检出率最低的是AMA。各抗体均以低滴度为主。ANA荧光模型以颗粒型为主。血清AFP含量的高低与自身抗体检出率之间未见明显相关性。HBV-DNA阳性患者与HBV-DNA阴性患者自身抗体检出率差异无统计学意义。女性患者自身抗体检出率明显高于男性。 Objective:To study the characteristics of autoantibodies in patients with primary hepatocellular carcinoma(HCC).Methods:83 patients with primary hepatocellular carcinoma(HCC)were studied.Different autoantibodies were detected by indirect immunofluorescent assay(IIF,Euroimmuno,Germany).Results:31 of 83 cases were found autoantibodies(37.3%),in whom 64 patients were in HBV infection,with 23 autoantibodies positive(35.9%).8 were autoantibody-positive in 16 patients with HCV infection(50.0%).There was no significant differences between the two groups(P0.05).24.1%(20/83)or 12.1%(10/83)or 1.2%(1/83)patients were positive for one,two or three kinds of autoantibodies respectively.Anti-nuclear antibody(ANA)was the most popular(24.1%)than others.Anti-cytoskeleton(CS)was 13.3%,whereas anti-smooth muscle antibody(SMA)was 9.6% and anti-mitochondria antibody(AMA)4.8% respectively.It was shown that anti-Ro-52 or anti-CENP-B was positive by ANA analysis.Comparing AFP normal with abnormal patients,antoantibody rate(22.2% vs 36.8%)had no significant difference.There were no remarkable difference between autoantibodies positive group and autoantibodies negative group for HBV-DNA.Conclusion:Non-organ-specific autoantibodies—ANA,CS,SMA and AMA can be detected in 37.3% patients with HCC.The highest detection rate is ANA,the next is CS and SMA,and the lowest is AMA.All of detected autoantibodies are shown with low titer(1∶100).Concentration of AFP and autoantibodies is not shown significant correlation.There is no remarkable difference in autoantibodies between HBV-DNA positive group and negative group.
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2010年第12期1127-1129,1132,共4页 Chinese Journal of Immunology
基金 北京市自然科学基金资助项目(No.7092046)
关键词 原发性肝癌 自身抗体 检测 Hepatocellular carcinoma Autoantibodies Detection
  • 相关文献

参考文献9

二级参考文献47

共引文献103

同被引文献37

  • 1杨朝国,吴磊,王明谊.癌症患者血清自身抗体的临床意义探讨[J].国外医学(临床生物化学与检验学分册),2005,26(12):942-943. 被引量:8
  • 2Bosch, FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends[ J ]. Gsatroenterology, 2004, 127 (5 Suppl 1) : S5-S16. DOI:10. 1053/j. gastro. 2004.09. 011.
  • 3Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening[J] . Semin Liver Dis, 2005, 25 (2): 143- 154. DOI:IO. 1055/S-200S-871194.
  • 4Liu C, Shen J, Pan C, et al. MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of hepatocellular carcinoma[ J ]. Am J Clin Pathol, 2010, 134 (2) : 235-241. DOI: 10. 1309/AJCPA6C6NOGFLYIR.
  • 5Xiao JF, Varghese RS, Zhou B, et al. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort[J]. J Proteome Res, 2012, 11 (12) : 5914-5923. DOI : 10. 1021/pr300673x.
  • 6Tomer Y, Sherer Y, Shoenfeld Y. Autoantibodies, autoimmunity and cancer (review) [J]. Oncol Rep, 1998, 5 (3): 753- 761. DOI : 10. 1016/13978-044450331-2/50016-3.
  • 7Reuschenbach M, von Knebel Doeberitz M, Wentzensen N. A systematic review of humoral immune responses against tumor antigens[ J]. Cancer immunol Immunother, 2009, 58 (10) : 1535-1544. DOI: 10. 1007/s00262-009-0733-4.
  • 8Hanash S. Harnessing immunity for cancer marker discovery [ J ]. Nat biotechnol, 2003, 21 ( 1 ) : 37-38. DOI: 10. 1038/nbto103- 37.
  • 9Imai H, Furuta K, Landberg G, et al. Autoantibody to DNA topoisomerase II in primary liver cancer [ J ]. Clin Cancer Res, 1995, 1(4) : 417-424.
  • 10Imai H, Nakano Y, Kiyosawa K, et al. Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma [ J]. Cancer, 1993, 71 (1): 26-35. DOI: 10. 1002/1097-0142 ( 19930101 ).

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部